Test. Inform. Manage.

Xpert® SA Nasal Complete

Detection of *S. aureus* and MRSA Colonization In About an Hour.
A rapid test for both SA and MRSA colonization has many applications, including assisting physicians in targeting appropriate prophylactic therapy and decolonization to reduce the risk of post-surgical site infections.”

Samir S. Awad M.D.
Associate Professor
Michael E. DeBakey Dept. of Surgery
Baylor College of Medicine, Houston TX
Director of Surgical Intensive Care Unit
Veteran Affairs Medical Center, Houston

THE NEED

Staphylococcus aureus infections are an increasingly serious public health issue.

Colonized patients at risk for serious complications include surgical, trauma, burn and dialysis patients:

- S. aureus colonized patients are up to 9 times more likely to develop surgical site infections than non-carriers1
- S. aureus is the major cause of access infections and bacteremia in dialysis patients2
- Carriage is the major risk factor for infection with S. aureus in dialysis patients4
- Up to 93% of nosocomial S. aureus infections are caused by a patient’s own flora3,4
- SA and MRSA infections are associated with increases in length of hospital stay, costs, morbidity, and mortality6,7,11
- Nasal carriage of S. aureus and self-infection of wounds in ICU/Burn patients is well documented9,10

THE SOLUTION

Rapid and accurate detection of colonization facilitates targeted infection control practices:

- Optimize pre-admission workflow and counseling
- Enables measures to reduce endogenous infection risk, including decolonization
- Supports measures to reduce exogenous infection risk, including barrier/contact precautions
- Aligns with infection control strategies as outlined by SCIP and SHEA/IDSA
**THE IMPACT**

Surgical Site Infections (SSIs) due to SA & MRSA significantly increase risk of death, costs and hospitalization as compared to surgeries without SSIs.\(^6\)\(^7\)

![Graph showing risk of death, length of stay, and costs for SSIs due to SA vs. MRSA.](image)

Rapid detection and implementation of targeted control measures improves your bottom line by reducing adverse medical care events.

Hospitals absorb most of the costs for adverse medical care events, as in the example below.

**Costs of Central Line Associated Bloodstream Infection (CLAB)**\(^5\)

<table>
<thead>
<tr>
<th>Avg reimbursement per case</th>
<th>Avg cost per case with CLAB</th>
<th>Avg loss per case</th>
</tr>
</thead>
<tbody>
<tr>
<td>$64,894</td>
<td>$91,733</td>
<td>$26,839</td>
</tr>
</tbody>
</table>

**THE PERFORMANCE**

Performance Characteristics of Xpert\(^\text{®} \) SA Nasal Complete Compared to MRSA and SA Direct Culture Method*  

<table>
<thead>
<tr>
<th></th>
<th>MRSA+</th>
<th>SA+/MRSA-</th>
<th>Neg/No Growth</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Xpert MRSA+</strong></td>
<td>159</td>
<td>24</td>
<td>25</td>
<td>208</td>
</tr>
<tr>
<td><strong>Xpert SA+/MRSA-</strong></td>
<td>9</td>
<td>393</td>
<td>152</td>
<td>554</td>
</tr>
<tr>
<td><strong>Xpert SA-</strong></td>
<td>5</td>
<td>37</td>
<td>1683</td>
<td>1725</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>173</td>
<td>454</td>
<td>1860</td>
<td>2487</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Culture +</th>
<th>Culture -</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Xpert MRSA +</strong></td>
<td>159</td>
<td>49</td>
<td>208</td>
</tr>
<tr>
<td><strong>Xpert MRSA -</strong></td>
<td>14</td>
<td>2265</td>
<td>2279</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>173</td>
<td>2314</td>
<td>2487</td>
</tr>
</tbody>
</table>

Sensitivity: 91.9%  
PPV: 76.4%  
Specificity: 97.9%  
NPV: 99.4%

<table>
<thead>
<tr>
<th></th>
<th>Culture +</th>
<th>Culture -</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Xpert SA +</strong></td>
<td>585</td>
<td>177</td>
<td>762</td>
</tr>
<tr>
<td><strong>Xpert SA -</strong></td>
<td>42</td>
<td>1683</td>
<td>1725</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>627</td>
<td>1860</td>
<td>2487</td>
</tr>
</tbody>
</table>

Sensitivity: 93.3%  
PPV: 76.8%  
Specificity: 90.5%  
NPV: 97.6%

* Xpert SA Nasal Complete Package Insert

---

Račionalno odgovora na zahtevanje.
WORKFLOW:
3 EASY STEPS
Total hands-on time: <1 Minute

1. Insert swab into Sample Reagent vial and break
2. Vortex and dispense Sample into Port S
3. Insert Cartridge and start assay

Ordering Information
Xpert® SA Nasal Complete (10 tests) Catalog No. GXSACOMP-10

References:

For In Vitro Diagnostic Use.